AI Terminal
POLAREAN IMAGING PLC
Board/Management Information • Dec 4, 2020
7850_rns_2020-12-04_879ff709-f2a3-4965-b201-ab059847aadb.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5284H
Polarean Imaging PLC
04 December 2020
Polarean Imaging Plc
("Polarean" or the "Company")
Appointment of Joint Corporate Broker
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as Joint Corporate Broker with immediate effect.
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | ||
| Richard Hullihen, Chief Executive Officer Jonathan Allis, Chairman |
Via Walbrook PR | ||
| SP Angel Corporate Finance LLP Nomad and Broker | Tel: +44 (0)20 3470 0470 | ||
| David Hignell / Adam Cowl (Corporate Finance) | |||
| Vadim Alexandre / Rob Rees (Corporate Broking) | |||
| Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | ||
| Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) | |||
| Nick Adams / Fred Walsh (Corporate Broking) | |||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | ||
| Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001 | ||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPZZMGZMFZGGZZ